Calcitonin affects both bone and cartilage: A dual action treatment for osteoarthritis?

Annals of the New York Academy of Sciences

Volumn 1117, Issue , 2007, Pages 181-195

  Karsdal, Morten Asser ^a   Sondergaard, Bodil C ^a   Arnold, Michel ^b   Christiansen, Claus ^a  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Calcitonin; Cartilage; Osteoarthritis; Osteoclasts

Indexed keywords

CALCITONIN; CALCITONIN RECEPTOR; CYCLIC AMP; MATRIX METALLOPROTEINASE; PROTEINASE; PROTEOGLYCAN;

ARTICULAR CARTILAGE; BIOSYNTHESIS; BONE DENSITY; BONE TURNOVER; CARTILAGE CELL; CARTILAGE DEGENERATION; CHONDROPROTECTION; CONFERENCE PAPER; CYTOLOGY; DISEASE MODEL; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; OSSIFICATION; OSTEOARTHRITIS; PROTEOGLYCAN SYNTHESIS;

ANIMALIA;

EID: 36549027898     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1196/annals.1402.041     Document Type: Conference Paper

References (77)

1. ABRAMSON, S.B., M. ATTUR & Y. YAZICI. 2006. Prospects for disease modification in osteoarthritis. Nat. Clin. Pract.Rheumatol. 2: 304-312.
2. FELSON, D.T. & T. NEOGI. 2004. Osteoarthritis: is it a disease of cartilage or of bone? Arthritis Rheum. 50: 341-344.
3. HAYAMI, T., M. PICKARSKI, G.A. WESOLOWSKI, et al. 2004. The role of subchondral bone remodeling in osteoarthritis: reduction of cartilage degeneration and prevention of osteophyte formation by alendronate in the rat anterior cruciate ligament transection model. Arthritis Rheum. 50: 1193-1206.
4. KIANI, C., L. CHEN, Y.J. WU, et al. 2002. Structure and function of aggrecan. Cell. Res. 12: 19-32.
5. LITTLE, C.B., L. MITTAZ, D. BELLUOCCIO, et al. 2005. ADAMTS-1-knockout mice do not exhibit abnormalities in aggrecan turnover in vitro or in vivo. Arthritis Rheum. 52: 1461-1472.
6. STANTON, H., F.M. ROGERSON, C.J. EAST, et al. 2005. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature 434: 648-652.
7. LITTLE, C.B., C.T. MEEKER, R.M. HEMBRY, et al. 2005. Matrix metalloproteinases are not essential for aggrecan turnover during normal skeletal growth and development. Mol. Cell Biol. 25: 3388-3399.
8. COLLINS-RACIE, L.A., C.R. FLANNERY, W. ZENG, et al. 2004. ADAMTS-8 exhibits aggrecanase activity and is expressed in human articular cartilage. Matrix Biol. 23: 219-230.
9. MORT, J.S., C.R. FLANNERY, J. MAKKERH, et al. 2003. Use of anti-neoepitope antibodies for the analysis of degradative events in cartilage and the molecular basis for neoepitope specificity. Biochem. Soc. Symp. 70: 107-114.
10. TANG, B.L. 2001. ADAMTS: a novel family of extracellular matrix proteases. Int. J. Biochem. Cell Biol. 33: 33-44.
11. KOSHY, P.J., C.J. LUNDY, A.D. ROWAN, et al. 2002. The modulation of matrix metalloproteinase and ADAM gene expression in human chondrocytes by interleukin-1 and oncostatin M: a time-course study using real-time quantitative reverse transcription-polymerase chain reaction. Arthritis Rheum. 46: 961-967.
12. DEAN, D.D., J. MARTEL-PELLETIER, J.P. PELLETIER, et al. 1989. Evidence for metalloproteinase and metalloproteinase inhibitor imbalance in human osteoarthritic cartilage. J. Clin. Invest. 84: 678-685.
13. MARTEL-PELLETIER, J., N. ALAAEDDINE & J.P. PELLETIER. 1999. Cytokines and their role in the pathophysiology of osteoarthritis. Front Biosci. 4: D694-D703.
14. REBOUL, P., J.P. PELLETIER, G. TARDIF, et al. 1996. The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes. A role in osteoarthritis. J. Clin. Invest. 97: 2011-2019.
15. PELLETIER, J.P., C. BOILEAU, J. BRUNET, et al. 2004. The inhibition of subchondral bone resorption in the early phase of experimental dog osteoarthritis by licofelone is associated with a reduction in the synthesis of MMP-13 and cathepsin K. Bone 34: 527-538.
16. HELMINEN, H.J., A.M. SAAMANEN, H. SALMINEN & M.M. HYTTINEN. 2002. Transgenic mouse models for studying the role of cartilage macromolecules in osteoarthritis. Rheumatology (Oxf.) 41: 848-856.
17. VAN DEN BERG, W.B. 2002. Lessons from animal models of arthritis. Curr. Rheumatol. Rep. 4: 232-239.
18. HUI, W., A.D. ROWAN, C.D. RICHARDS & T.E. CAWSTON. 2003. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum. 48: 3404-3418.
19. SCHALLER, S., K. HENRIKSEN, P. HOEGH- ANDERSEN, et al. 2005. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist? Assay Drug Dev. Technol. 3: 553-580.
20. RYU, J., H.J. KIM, E.J. CHANG, et al. 2006. Sphingosine 1-phosphate as a regulator of osteoclast differentiation and osteoclast-osteoblast coupling. EMBO J. 25: 5840-5851.
21. MOURITZEN, U., S. CHRISTGAU, H.J. LEHMANN, et al. 2003. Cartilage turnover assessed with a newly developed assay measuring collagen type II degradation products: influence of age, sex, menopause, hormone replacement therapy, and body mass index. Ann. Rheum. Dis. 62: 332-336.
22. OLIVERIA, S.A., D.T. FELSON, J.I. REED, et al. 1995. Incidence of symptomatic hand, hip, and knee osteoarthritis among patients in a health maintenance organization. Arthritis Rheum. 38: 1134-1141.
23. HAM, K.D. & C.S. CARLSON. 2004. Effects of estrogen replacement therapy on bone turnover in subchondral bone and epiphyseal metaphyseal cancellous bone of ovariectomized cynomolgus monkeys. J. Bone. Miner. Res. 19: 823-829.
24. HAM, K.D., R.F. LOESER, B.R. LINDGREN & C.S. CARLSON. 2002. Effects of long-term estrogen replacement therapy on osteoarthritis severity in cynomolgus monkeys. Arthritis Rheum. 46: 1956-1964.
25. CARBONE, L.D., M.C. NEVITT, K. WILDY, et al. 2004. The relationship of antiresorptive drug use to structural findings and symptoms of knee osteoarthritis. Arthritis Rheum. 50: 3516-3525.
26. HAYAMI, T., M. PICKARSKI, Y. ZHUO, et al. 2006. Characterization of articular cartilage and subchondral bone changes in the rat anterior cruciate ligament transection and meniscectomized models of osteoarthritis. Bone 38(2): 234-243.
27. GARNERO, P., C. PETERFY, S. ZAIM & M. SCHOENHARTING. 2005. Bone marrow abnormalities on magnetic resonance imaging are associated with type II collagen degradation in knee osteoarthritis: a three-month longitudinal study. Arthritis Rheum. 52: 2822-2829.
28. FELSON, D.T. & M.C. NEVITT. 1998. The effects of estrogen on osteoarthritis. Curr. Opin. Rheumatol. 10: 269-272.
29. HUNTER, D.J., D. HART, H. SNIEDER, et al. 2003. Evidence of altered bone turnover, vitamin D and calcium regulation with knee osteoarthritis in female twins. Rheumatology (Oxf.) 42: 1311-1316.
30. HUNTER, D.J. & T.D. SPECTOR. 2003. The role of bone metabolism in osteoarthritis. Curr. Rheumatol. Rep. 5: 15-19.
31. DIEPPE, P., J. CUSHNAGHAN, P. YOUNG & J. KIRWAN. 1993. Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy. Ann. Rheum. Dis. 52: 557-563.
32. ARDEN, N. & M.C. NEVITT. 2006. Osteoarthritis: epidemiology. Best. Pract. Res. Clin. Rheumatol. 20: 3-25.
33. CALVO, E., S. CASTANEDA, R. LARGO, et al. 2007. Osteoporosis increases the severity of cartilage damage in an experimental model of osteoarthritis in rabbits. Osteoarthritis Cartilage 15: 69-77.
34. CHRISTGAU, S., L.B. TANKO, P.A. CLOOS, et al. 2004. Suppression of elevated cartilage turnover in postmenopausal women and in ovariectomized rats by estrogen and a selective estrogen-receptor modulator (SERM). Menopause 11: 508-518.
35. MA, H.L., T.J. BLANCHET, D. PELUSO, et al. 2007. Osteoarthritis severity is sex dependent in a surgical mouse model. Osteoarthritis Cartilage 15: 695-700.
36. HOEGH-ANDERSEN, P., L.B. TANKO, T.L. ANDERSEN, et al. 2004. Ovariectomized rats as a model of postmenopausal osteoarthritis: validation and application. Arthritis Res. Ther. 6: R169-R180.
37. SEXTON, P.M., D.M. FINDLAY & T.J. MARTIN. 1999. Calcitonin. Curr. Med. Chem. 6: 1067-1093.
38. DEFTOS, L.J. 2006. Calcitonin. In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. Sixth edition. 115-117 (Abstr.)
39. COPP, D.H., E.C. CAMERON, B.A. CHENEY, et al. 1962. Evidence for calcitonin-a new hormone from the parathyroid that lowers blood calcium. Endocrinology 70: 638-649.
40. KUMAR, M.A., G.V. FOSTER & I. MACINTYRE. 1963. Further evidence for calcitonin. A rapid-acting hormone which lowers plasma-calcium. Lancet 35: 480-482.
41. CHAMBERS, T.J. & A. MOORE. 1983. The sensitivity of isolated osteoclasts to morphological transformation by calcitonin. J. Clin. Endocrinol. Metab. 57: 819-824.
42. SUZUKI, H., I. NAKAMURA, N. TAKAHASHI, et al. 1996. Calcitonin-induced changes in the cytoskeleton are mediated by a signal pathway associated with protein kinase A in osteoclasts. Endocrinology 137: 4685-4690.
43. SHYU, J.F., C. SHIH, C.Y. TSENG, et al. 2007. Calcitonin induces podosome disassembly and detachment of osteoclasts by modulating Pyk2 and Src activities. Bone 40: 1329-1342.
44. SORENSEN, M.G., K. HENRIKSEN, S. SCHALLER, et al. 2007. Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J. Bone Miner. Metab. 25: 36-45.
45. TANKO, L.B., Y.Z. BAGGER, P. ALEXANDERSEN, et al. 2004. Safety and efficacy of a novel salmon calcitonin (sCT) technology-based oral formulation in healthy postmenopausal women: acute and 3-month effects on biomarkers of bone turnover. J. Bone Miner. Res. 19: 1531-1538.
46. OVERGAARD, K. & C. CHRISTIANSEN. 1991. Long-term treatment of established osteoporosis with intranasal calcitonin. Calcif. Tissue Int. 49(Suppl): S60-S63.
47. OVERGAARD, K., B.J. RIIS, C. CHRISTIANSEN, et al. 1989. Nasal calcitonin for treatment of established osteoporosis. Clin. Endocrinol. (Oxf.) 30: 435-442.
48. PURDUE, B.W., N. TILAKARATNE & P.M. SEXTON. 2002. Molecular pharmacology of the calcitonin receptor. Receptors Channels 8: 243-255.
49. MANICOURT, D.H., J.P. DEVOGELAER, M. AZRIA & S. SILVERMAN. 2005. Rationale for the potential use of calcitonin in osteoarthritis. J. Musculoskelet. Neuronal. Interact. 5: 285-293.
50. KARSDAL, M.A., L.B. TANKO, B.J. RIIS, et al. 2006. Calcitonin is involved in cartilage homeostasis: is calcitonin a treatment for OA? Osteoarthritis Cartilage. 14: 617-624.
51. FRANCHIMONT, P., C. BASSLEER, Y. HENROTIN, et al. 1989. Effects of human and salmon calcitonin on human articular chondrocytes cultivated in clusters. J. Clin. Endocrinol. Metab. 69: 259-266.
52. HELLIO, M.P., M.J. PESCHARD, C. COHEN, et al. 1997. Calcitonin inhibits phospholipase A2 and collagenase activity of human osteoarthritic chondrocytes. Osteoarthritis Cartilage 5: 121-128.
53. BAXTER, E., J.R. FRASER, G.S. HARRIS, et al. 1968. Stimulation of glycosaminoglycan synthesis by thyrocalcitonin preparations. Med. J. Aust. 1: 216-217.
54. MARTIN, T.J., G.S. HARRIS, R.A. MELICK & J.R. FRASER. 1969. Effect of calcitonin on glycosaminoglycan synthesis by embryo calf bone cells in vitro. Experientia 25: 375-376.
55. KATO, Y., N. NASU, T. TAKASE, et al. 1980. A serum-free medium supplemented with multiplication-stimulating activity (MSA) supports both proliferation and differentiation of chondrocytes in primary culture. Exp. Cell Res. 125: 167-174.
56. DESHMUKH, K., W.G. KLINE & B.D. SAWYER. 1977. Effects of calcitonin and parathyroid hormone on the metabolism of chondrocytes in culture. Biochim. Biophys. Acta 499: 28-35.
57. DI NINO, D.L. & T.F. LINSENMAYER. 2003. Positive regulation of endochondral cartilage growth by perichondrial and periosteal calcitonin. Endocrinology 144: 1979-1983.
58. BURCH, W.M. & G. CORDA. 1985. Calcitonin stimulates maturation of mammalian growth plate cartilage. Endocrinology 116: 1724-1728.
59. BURCH, W.M. 1984. Calcitonin stimulates growth and maturation of embryonic chick pelvic cartilage in vitro. Endocrinology 114: 1196-1202.
60. SUZUKI, F., T. YONEDA & Y. SHIMOMURA. 1976. Calcitonin and parathyroid-hormone stimulation of acid mucopolysaccharide synthesis in cultured chondrocytes isolated from growth cartilage. FEBS Lett. 70: 155-158.
61. MANICOURT, D.H., R.D. ALTMAN, J.M. WILLIAMS, et al. 1999. Treatment with calcitonin suppresses the responses of bone, cartilage, and synovium in the early stages of canine experimental osteoarthritis and significantly reduces the severity of the cartilage lesions. Arthritis Rheum. 42: 1159-1167.
62. EL HAJJAJI, H., J.M. WILLIAMS, J.P. DEVOGELAER, et al. 2004. Treatment with calcitonin prevents the net loss of collagen, hyaluronan and proteoglycan aggregates from cartilage in the early stages of canine experimental osteoarthritis. Osteoarthritis Cartilage 12: 904-911.
63. BEHETS, C., J.M. WILLIAMS, D. CHAPPARD, et al. 2004. Effects of calcitonin on subchondral trabecular bone changes and on osteoarthritic cartilage lesions after acute anterior cruciate ligament deficiency. J. Bone Miner. Res. 19: 1821-1826.
64. SONDERGAARD, B.C., H. WULF, K. HENRIKSEN, et al. 2006. Calcitonin directly attenuates collagen type II degradation by inhibition of matrix metalloproteinase expression and activity in articular chondrocytes. Osteoarthritis Cartilage 14: 759-768.
65. KHALDI, L., T. KARACHALIOS, A. GALANOS & G.P. LYRITIS. 2005. Morphometric changes in the epiphyseal plate of the growing and young adult male rat after long-term salmon calcitonin administration. Calcif. Tissue Int. 76: 426-432.
66. PAPAIOANNOU, N.A., I.K. TRIANTAFILLOPOULOS, L. KHALDI, et al. 2007. Effect of calcitonin in early and late stages of experimentally induced osteoarthritis. A histomorphometric study. Osteoarthritis Cartilage 15(4): 386-395.
67. BADURSKI, J.E., W. SCHWAMM, J. POPKO, et al. 1991. Chondroprotective action of salmon calcitonin in experimental arthropathies. Calcif. Tissue Int. 49: 27-34.
68. KARSDAL, M.A., E.U. SUMER, H. WULF, et al. 2007. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum. 56: 1549-1558.
69. SONDERGAARD, B.C., E.U. SUMER, S.H. MADSEN, et al. 2007. Calcitonin stimulates the synthesis of proteoglycans and inhibits the aggrecanase activity mediated degradation in human osteoarthritic cartilage ex vivo. Ann. Rheum. Dis. 66: S116 (Abstr.)
70. KARSDAL, M.A., L. LARSEN, M.T. ENGSIG, et al. 2002. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J. Biol. Chem. 277: 44061-44067.
71. SONDERGAARD, B.C., K. HENRIKSEN, H. WULF, et al. 2006. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage 14: 738-748.
72. SONDERGAARD, B.C., S. OSTERGAARD, C. CHRISTIANSEN & M.A. KARSDAL. 2007. The effects of oral calcitonin on cartilage turnover and cartilage erosion in the ovariectomized rat model. Arthritis Rheum. 56(8): 2674-2678.
73. SONDERGAARD, B.C., K. HENRIKSEN, S. OESTERGAARD, et al. 2005. Calcitonin has direct chondroprotective effects. Arthritis Rheum. 52: S57 (Abstr.)
74. BAGGER, Y.Z., L.B. TANKO, P. ALEXANDERSEN, et al. 2005. Oral salmon calcitonin induced suppression of urinary collagen type II degradation in postmenopausal women: a new potential treatment of osteoarthritis. Bone 37: 425-430.
75. MANICOURT, D.H., M. AZRIA, L. MINDEHOLM, et al. 2006. Oral salmon calcitonin reduces Lequesne's algofunctional index scores and decreases urinary and serum levels of biomarkers of joint metabolism in knee osteoarthritis. Arthritis Rheum. 54: 3205-3211.
76. REIJMAN, M., J.M. HAZES, S.M. BIERMA- ZEINSTRA, et al. 2004. A new marker for osteoarthritis: cross-sectional and longitudinal approach. Arthritis Rheum. 50: 2471-2478.
77. SONDERGAARD, B.C., A.K. OLSEN, E.U. SUMER, et al. 2005. Calcitonin stimulates proteoglycan and collagen type ii biosynthesis in articular cartilage ex vivo. Ostearthritis Cartilage 13: 142.